The regimen under investigation pairs trifluridine/tipiracil, an oral drug commonly abbreviated as FTD/TPI, with nanoliposomal irinotecan, a nanoparticle-encapsulated formulation of the classic chemotherapy agent irinotecan. Both components have already demonstrated clinical activity in gastrointestinal malignancies, but the logic of the combination goes deeper than convenience. Trifluridine is a thymidine analog that incorporates itself into replicating DNA and disrupts synthesis, while tipiracil inhibits the enzyme that would otherwise rapidly degrade trifluridine in the liver, thereby sustaining effective drug levels after oral administration. Nanoliposomal irinotecan, meanwhile, wraps the topoisomerase I inhibitor irinotecan inside a lipid bilayer roughly one hundred nanometers across, prolonging its circulation in the bloodstream and altering its distribution toward tumor tissue. The researchers hypothesize that these two mechanisms may produce synergistic antitumor effects when deployed together.

TRITICC-2 is structured as a prospective, open-label, multicenter, single-arm phase II trial conducted at academic centers across Germany. The single-arm design means that all enrolled patients receive the experimental combination, and results will be compared against historical benchmarks rather than a concurrent control group. This approach is common for early-phase studies in rare cancers, where the small patient population makes randomized designs difficult and slow. A total of 38 patients are planned for enrollment, all of whom must have histologically confirmed, unresectable or metastatic biliary tract cancer and documented disease progression on gemcitabine-based first-line therapy. Recruitment was initiated in late 2025 and is ongoing, with efficacy, safety, and translational analyses still pending.

The treatment schedule reflects a careful balancing of efficacy against toxicity. Patients receive oral trifluridine/tipiracil on days one through five of each cycle, combined with an intravenous infusion of nanoliposomal irinotecan on day one. Cycles repeat every fourteen days, and treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent. This two-week rhythm allows the oral component to hit the tumor repeatedly during each cycle while the long-circulating liposomal formulation maintains a sustained presence. The primary endpoint of the trial is progression-free survival, the length of time patients live without their disease advancing, which is a clinically meaningful measure in a setting where cure is not the realistic goal.

Secondary endpoints broaden the picture considerably. The investigators will track overall survival, the objective response rate as measured by standard imaging criteria, and the safety profile of the combination, graded according to the National Cancer Institute’s common toxicity criteria. Importantly, the trial also incorporates health-related quality of life assessments using validated instruments, including the EORTC QLQ-C30 questionnaire and the EQ-5D-5L. This attention to how patients actually feel and function during treatment matters enormously in a palliative setting, where a regimen that adds weeks of survival at the cost of debilitating side effects may offer little real benefit. The open-label design means patients and physicians know which treatment is being given, which is typical for trials of this size and phase but does introduce potential bias in subjective endpoints.

Beyond the clinical measurements, TRITICC-2 includes an optional translational research program that could prove scientifically valuable in its own right. Participants may undergo serial liquid biopsies, meaning repeated analyses of cell-free DNA and other biomarkers circulating in their blood, allowing researchers to track the molecular evolution of their tumors over time without repeated invasive tissue biopsies. By correlating these biomarker dynamics with treatment response and resistance, the investigators hope to identify markers associated with benefit from the combination. In an era when precision oncology increasingly depends on understanding which molecular features predict drug sensitivity, such prospective translational data from a rare cancer are genuinely scarce and correspondingly precious.

The trial’s governance structure follows the rigorous standards expected of modern European clinical research. The study is registered under the European Union Clinical Trials Regulation with the number EUCT 2024-517330-18-00, and its protocol is publicly accessible through the CTIS portal. Heinrich-Heine-University Düsseldorf serves as the sponsor, while the study is fully funded by Les Laboratoires Servier as an investigator-initiated trial, meaning the scientific questions and study design are driven by the academic investigators rather than the company. An independent data monitoring committee, composed of two gastroenterology specialists and one biostatistician, all of whom have declared no competing interests, reviews safety data twice a year and can request additional reviews at any time, with authority to recommend continuation, modification, or termination of the trial.

Quality assurance measures embedded in the protocol underscore the seriousness of the effort. A risk-based monitoring strategy ensures that every participating site receives at least one on-site visit per year, with visits concentrated on the data and processes most critical to study integrity. These on-site activities are complemented by centralized monitoring performed by data managers and biostatisticians. Written informed consent is required from all participants, and the trial operates under Good Clinical Practice standards and the German Medicine Act. Notably, no interim efficacy analyses are planned, which avoids the statistical complications of repeatedly testing the data, and the investigators have committed to publishing results regardless of whether the outcome is positive or negative, a pledge that remains disappointingly rare in clinical research.

For patients with advanced biliary tract cancer, the stakes of this trial could hardly be higher. The disease encompasses cholangiocarcinoma in its intrahepatic, perihilar, and distal forms as well as gallbladder carcinoma, and together these malignancies account for a substantial burden of cancer mortality worldwide, with incidence rising in many countries. Second-line treatment options after gemcitabine failure have historically delivered limited benefit, and while molecularly targeted therapies have emerged for the small subset of patients with actionable mutations such as IDH1 or FGFR2 alterations, the majority of patients still lack personalized options. A well-tolerated, orally anchored combination regimen could, if successful, offer a practical new standard that does not require specialized molecular testing infrastructure.

The TRITICC-2 study also illustrates a broader trend in oncology drug development: the intelligent repurposing of established agents into rational combinations for underserved tumor types. Neither trifluridine/tipiracil nor nanoliposomal irinotecan is a new molecule, but their pairing applies mechanistic reasoning and formulation science to a population with high unmet medical need. With enrollment underway and results still to come, the trial will not deliver answers immediately. Yet its design, transparency, and translational ambitions make it a study worth watching, both for the patients it may ultimately help and for the biomarker insights it may generate about how biliary tract cancers evolve and evade treatment.

Subject of Research: A phase II trial of trifluridine/tipiracil plus nanoliposomal irinotecan as second-line therapy for advanced biliary tract cancer

Article Title: Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2)

Article References: Kehmann, L., Götze, T., Gonzalez-Carmona, M., Foerster, F., Berres, M., Mohr, R., Koch, A., Das, S., Drusenheimer, N., Kebede, T., Joerdens, M., Luedde, T., & Roderburg, C. (2026). Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2). BMC Cancer. https://doi.org/10.1186/s12885-026-17089-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17089-6

Keywords: biliary tract cancer, cholangiocarcinoma, trifluridine/tipiracil, nanoliposomal irinotecan, phase II trial, second-line therapy, progression-free survival, liquid biopsy, clinical trial, oncology, chemotherapy, translational research

The study, led by Tomás José González-López of Hospital Universitario de Burgos and colleagues across 22 Spanish centers, analyzed 72 adults with ITP drawn from a broader national cohort of 174 patients who had received the drug. The median age of participants was 67 years, and 55.6 percent were women, a demographic profile that reflects the typical real-world ITP population far better than the carefully selected patients enrolled in pharmaceutical registration trials. Half of the patients carried at least one comorbidity on the Charlson Comorbidity Index, and roughly a quarter had experienced bleeding in the month before starting fostamatinib, underscoring the clinical urgency that often drives treatment decisions in this disease.

ITP is an acquired immune-mediated disorder in which platelet counts fall because of a double hit: antibodies and cytotoxic T lymphocytes accelerate platelet destruction in the spleen and elsewhere, while defective megakaryocyte maturation impairs the production of replacement platelets in the bone marrow. The clinical course is highly variable. Some patients remain asymptomatic despite platelet counts well below 100 × 10⁹ per liter, while others suffer significant mucocutaneous bleeding or develop chronic, relapsing disease that demands years of therapy. Beyond the bleeding risk itself, ITP carries a substantial burden on quality of life and healthcare resources, particularly for patients who cycle through multiple treatment lines without achieving durable control.

Standard first-line therapy remains corticosteroids, sometimes supplemented by intravenous immunoglobulin when rapid platelet increases are needed. Although initial steroid responses are high, relapse after dose tapering is common, and many patients become corticosteroid-dependent with all the metabolic and infectious complications that entails. Second-line options include thrombopoietin receptor agonists such as eltrombopag and romiplostim, the anti-CD20 antibody rituximab, and splenectomy. Each has drawbacks: TPO receptor agonists require continuous administration and raise concerns about thromboembolic risk in some patients, while rituximab and splenectomy can produce durable remissions but carry delayed onset, variable long-term efficacy, and procedure- or immunosuppression-related hazards. Guidelines therefore emphasize individualized sequencing, and the search for well-tolerated earlier options has intensified.

Fostamatinib attacks the disease from a different angle. As an oral inhibitor of spleen tyrosine kinase, or SYK, it interferes with Fcγ receptor signaling in macrophages, the scavenger cells that phagocytose antibody-coated platelets. By blocking this pathway, the drug reduces antibody-dependent platelet destruction rather than simply stimulating platelet production. Its efficacy and safety were established in the pivotal phase 3 FIT trials in patients with persistent and chronic ITP who had already received multiple prior therapies, leading to regulatory approval for chronic ITP in adults refractory to other treatments. But those trials, by design, tested the drug late in the disease course, leaving a gap in evidence about how it performs when introduced earlier.

The new Spanish study was designed to fill that gap. Patients received fostamatinib at the European Medicines Agency-approved starting dose of 100 milligrams twice daily, with escalation to 150 milligrams twice daily after four weeks if platelet responses were inadequate and tolerability permitted. Fifty-six point nine percent of patients ultimately required the higher dose, typically after a median of 24 days. Forty patients, or 55.5 percent, took fostamatinib as monotherapy throughout their treatment, while the remainder used it alongside tapering corticosteroids, immunoglobulin, or other agents. The median time from ITP diagnosis to fostamatinib initiation was 17 months, and the baseline platelet count stood at just 28 × 10⁹ per liter.

The effectiveness results were striking. Overall, 83.3 percent of patients achieved a response, defined as a platelet count of at least 30 × 10⁹ per liter with at least a twofold increase from baseline, resolution of bleeding, and no rescue therapy within the preceding eight weeks. Complete response, meaning a platelet count of at least 100 × 10⁹ per liter, was reached by 65.3 percent. When fostamatinib was used as second-line therapy, 76.0 percent responded, with 56.0 percent achieving complete response; in the third-line setting, the figures rose to 87.2 percent and 70.2 percent respectively. The median time to platelet response was a brisk 10.5 days, and patients reached their peak platelet counts, a median of 140 × 10⁹ per liter, after a median of 62 days. Across the 42-month observation window, patients spent a cumulative 76.8 percent of their time in response.

Exploratory subgroup analyses hinted at interesting patterns, though the investigators caution that these were hypothesis-generating and based on small numbers. Response rates were higher among women than men, 92.5 versus 71.9 percent, and higher in chronic than in non-chronic ITP by the same margin. Patients previously treated with eltrombopag responded more often than those without such exposure, 96.3 versus 75.6 percent, while prior romiplostim exposure was associated with a lower rate. Notably, second-line use was associated with faster platelet recovery, a median of 32 days to peak count compared with 77 days for third-line use, suggesting that earlier introduction may speed benefit even when overall efficacy is similar. Twenty-seven point eight percent of patients discontinued the drug for insufficient effectiveness, and only four patients, 5.5 percent, managed to stop fostamatinib successfully after responding, indicating that the drug is best regarded as long-term maintenance therapy rather than a finite course.

Safety data were reassuring. Adverse events occurred in 44.4 percent of patients and were predominantly mild to moderate, with diarrhea, hypertension, and headache the most common complaints, generally manageable with symptomatic treatment. Only 15.3 percent of patients stopped the drug because of toxicity, and severe grade 3 to 4 events were infrequent. Three thromboembolic events occurred, two deep vein thromboses and one pulmonary embolism, but all three patients had established thrombotic risk factors unrelated to the drug, including advanced age, obesity, and immobilization. Given growing recognition that ITP itself carries an elevated thrombotic risk, the low incidence observed here, 4.2 percent, may represent a meaningful advantage for patients with cardiovascular comorbidities, a group well represented in this elderly cohort.

The findings align with a growing body of international real-world evidence, including the Spanish FOSTASUR study, the Italian GIMEMA ITP 1122 experience, and a post hoc analysis of the FIT trials that reported response rates of 94 percent and 86 percent for second- and third-line use respectively. The authors acknowledge the limitations inherent to an observational design without a control group, but the consistency across independent cohorts strengthens the case. Their conclusion is direct: fostamatinib should be considered earlier in the ITP treatment algorithm rather than reserved as a last resort, with prospective studies now needed to define the optimal timing and sequencing of a drug that, for many patients, may offer rapid, durable platelet recovery with an acceptable safety profile.

Subject of Research: Real-world effectiveness and safety of early-line fostamatinib therapy in adult immune thrombocytopenia

Article Title: Early Use of Fostamatinib in Immune Thrombocytopenia

Article References: González-López, T. J., Bermejo-Vega, N., Cardesa-Cabrera, R., Acedo, N., Luis-Navarro, J., Lakhwani, S., Bernat, S., Haces-Tirado, G. E., Galán, P., Lozano, M. L., Martínez-Carballeira, D., Hernández-Martin, R., Jimenez-Bárcenas, R., Navas-Elorza, B., Marcellini, S., Torres-Tienza, A., Perona-Blázquez, A., Benet, C., Fernandez-Jimenez, D., … García-Donás Gabaldón, G. (2026). Early Use of Fostamatinib in Immune Thrombocytopenia. Advances in Therapy. https://doi.org/10.1007/s12325-026-03769-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03769-z

Keywords: immune thrombocytopenia, fostamatinib, SYK inhibitor, second-line therapy, third-line therapy, platelet response, real-world study, hematology, autoimmune disease, drug safety, thrombosis risk, Spain

The research team set out to answer a deceptively simple question: at a major United States academic medical center, what proportion of patients with metastatic EGFR-mutated non-small-cell lung cancer actually receive second-line therapy after discontinuing first-line osimertinib? Prior real-world studies had painted a grim picture. An Italian cohort found that only 56 percent of patients who progressed on first-line osimertinib received further treatment. A European retrospective analysis reported that just 42 percent of 500 patients who started the drug went on to a second line, with 292 dying before any further therapy. A large United States community-based study found a second-line rate of 56 percent. Whether elite academic centers, with their multidisciplinary tumor boards, clinical trial portfolios, and abundant resources, might do better remained an open question, and one with real implications for how the FLAURA2 results should be interpreted.

To investigate, the researchers combed through medical records of patients treated at their institution between February 2018 and July 2024, ultimately identifying 115 evaluable patients with metastatic disease harboring a classical EGFR mutation, either an exon 19 deletion or the L858R substitution, who had been treated with first-line osimertinib monotherapy. The cohort was notably diverse: half the patients were Asian, 74 percent were women, 69 percent had never smoked, and 93 percent had adenocarcinoma histology. The median age at diagnosis was 69 years, eight years older than the median in FLAURA2. Thirty-seven percent had central nervous system involvement at diagnosis, a detail that matters because osimertinib’s ability to penetrate the blood-brain barrier is one of its clinical strengths. All patients underwent next-generation sequencing-based molecular profiling at diagnosis, with the single exception of six patients whose limited tissue samples permitted only rapid targeted PCR testing for EGFR.

The headline finding was sobering. Of the 115 patients, 57.4 percent, or 66 individuals, discontinued first-line osimertinib during the observation window. Among those 66 patients, 39.4 percent died or entered hospice without receiving further anticancer treatment, while 60.6 percent, or 40 patients, experienced disease progression and went on to second-line therapy. In other words, even at a well-resourced academic center in one of the world’s most medically dense cities, only about six in ten patients who stopped osimertinib lived long enough and remained well enough to receive another treatment. When the researchers ran a conservative sensitivity analysis assuming that ten patients lost to follow-up had also discontinued therapy without receiving a second line, the second-line rate fell to 52.6 percent. The conclusion was hard to escape: the FLAURA2 control arm, far from being an outlier, mirrored real-world academic practice with uncomfortable fidelity.

Beyond the second-line question, the study yielded rich survival data. Median time to treatment failure on first-line osimertinib was 25.3 months, consistent with prior reports of osimertinib’s effectiveness. For the 40 patients who reached second-line therapy, median time to treatment failure dropped sharply to 4.7 months, and for the 22 who reached third-line therapy it was 4.8 months, underscoring how quickly options narrow after the first targeted agent fails. Median overall survival for the entire cohort was 42.4 months. Roughly half of the patients still on first-line osimertinib at the data cutoff had been on treatment for at least 24 months, while the other half had been on it for less time, a reminder that a substantial fraction of patients derive durable benefit from the drug even as others slip away.

One of the study’s most striking findings concerned the tumor suppressor gene TP53. Nearly half of the patients, 48 percent, carried a concurrent TP53 mutation in their tumors, and the vast majority of these were classified as likely oncogenic in the OncoKB knowledgebase. Patients with TP53-mutated tumors fared dramatically worse: their median time to treatment failure was 15.7 months compared with 42.2 months for those with TP53 wild-type tumors, and their median overall survival was 29.6 months compared with a figure that had not yet been reached for the wild-type group at a lower bound of 63.5 months. In multivariate Cox regression controlling for age, race, central nervous system disease, smoking status, and EGFR mutation type, TP53 status remained independently significant, with adjusted hazard ratios of 4.69 for treatment failure and 4.25 for death. Age was the only other covariate that retained significance.

Who, then, was falling through the cracks? The data pointed squarely at age and frailty. Patients who did not receive second-line therapy had a median age of 77.7 years, more than a decade older than the median of 64.9 years among those who did, a difference that was highly statistically significant. Performance status told a related story: among patients with good performance status at diagnosis, 62.2 percent of those who discontinued osimertinib went on to second-line treatment, compared with 47.4 percent of those with poor performance status, though this difference did not reach statistical significance. Notably, most patients who entered hospice after progression had poor performance status at hospice initiation, and nearly half had declined from good to poor status between diagnosis and hospice. Interestingly, central nervous system disease at diagnosis made no difference in second-line rates, perhaps reflecting osimertinib’s efficacy against brain metastases, and TP53 mutation status also did not significantly alter the likelihood of receiving further treatment.

The regimens patients actually received after osimertinib reflected contemporary National Comprehensive Cancer Network recommendations. Chemotherapy dominated the second-line landscape at 72.5 percent of patients, followed by continuation of osimertinib alongside another agent at 22.5 percent, immune checkpoint inhibitors at 17.5 percent, and vascular endothelial growth factor inhibitors and amivantamab at 7.5 percent each. Third-line patterns were similar, with chemotherapy again most common at 50 percent. Attrition continued relentlessly down the line: of 40 patients on second-line therapy, 33 discontinued it, and 22 of those proceeded to a third line. The funnel narrows at every step, and each narrowing represents patients who died, entered hospice, or were too ill to continue.

The findings carry weighty implications for treatment strategy. Because so many patients never reach a second line, the authors argue that patients who are willing and eligible at diagnosis should consider receiving chemotherapy together with osimertinib upfront, regardless of TP53 status, rather than saving chemotherapy for later. Emerging evidence strengthens this logic: a post hoc analysis of the MARIPOSA trial showed that the combination of amivantamab and lazertinib improved overall survival specifically in patients with TP53 mutations, and the recently reported TOP trial found that adding chemotherapy to osimertinib extended progression-free survival from 15.6 to 34.0 months in patients with EGFR mutations and TP53 co-mutations, though overall survival data remain immature. The counterweight is toxicity, since both FLAURA2 and MARIPOSA showed that combination regimens roughly doubled the rate of grade 3 adverse events, and identifying which patients can safely avoid intensification, possibly through circulating tumor DNA monitoring, remains a crucial unanswered question.

Ultimately, the study’s most viral-worthy message may be its most uncomfortable one: the attrition between first-line and second-line treatment in metastatic EGFR-mutated lung cancer is not a trial artifact, a community-practice problem, or a resource issue that better institutions can simply fix. Roughly half of patients with metastatic disease, across driver mutations and treatment regimens, never receive a second line of therapy, and this single-institution academic cohort proved no exception. The gap between the promise of precision oncology and its delivery at the bedside persists even where the tools are most available, and closing it will require confronting the realities of age, declining performance status, and the biology of aggressive disease rather than assuming that excellence in one line of treatment guarantees a chance at the next.

Subject of Research: Second-line treatment patterns and outcomes after first-line osimertinib in metastatic EGFR-mutated non-small-cell lung cancer

Article Title: Second‐Line Therapy Following Osimertinib in Metastatic EGFR‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center

Article References: Rafizadeh, M., Bogdan, S., Lee, J., Garcia, C., Saxena, A., Zhou, K., & Parang, B. (2026). Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center. Cancer Reports, 9(9), Article e70693. https://doi.org/10.1002/cnr2.70693

Image Credits: AI Generated

DOI: 10.1002/cnr2.70693

Keywords: osimertinib, EGFR-mutated NSCLC, second-line therapy, FLAURA2, TP53 mutation, lung cancer, real-world evidence, chemotherapy combination, time to treatment failure, overall survival, academic medical center, precision oncology